Have you been treated with Raptiva for psoriasis?

Raptiva (Efalizumab) was a drug sold by Genentech for psoriasis. On April 8, 2009, Genentech announced it was voluntarily pulling Raptiva from the market. This follows the Feb. 19, 2009 FDA public health advisory about reports of a rare brain infection in people using this drug.

According to the FDA, there have been three confirmed cases and one possible case of progressive multifocal leukoencephalopathy (PML) in people taking Raptiva; three of those people died. PML is a rare and usually fatal disease of the central nervous system.
PML usually occurs in people whose immune systems have been severely weakened. It leads to an irreversible decline in neurologic function and death.

Raptiva was approved by the FDA in 2003. It is a once-weekly injection for adults with moderate to severe plaque psoriasis, who are candidates for systemic (whole body) therapy or phototherapy. Raptiva suppresses T-cells, a part of the immune system, to curb psoriasis. The risk of PML may markedly increase with a longer duration of Raptiva exposure since suppressing T-cells increases a patient’s susceptibility for infections. The exact time-dependent threshold when the risk for PML increases is unknown.

Drug: Raptiva (Efalizumab)
Condition: Psoriasis
Complications: Progressive multifocal leukoencephalopathy (PML). PML symptoms may include unusual weakness, loss of coordination, change in vision, difficulty speaking, and personality changes.

If you or a loved one has taken Raptiva and has experienced any complications, Click HERE for a free evaluation of your case by the Law Offices of Brian D. Witzer. Our vast knowledge and experience with neurological dysfunctions sets us apart from other firms.